menu search

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...

November 4, 2023, 5:37 pm

Scholar rock: sma data readout in 2024 makes this worth a look

The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollme...

October 25, 2023, 5:44 pm

Apellis pharmaceuticals shares rally as competing eye treatment fails to impress analysts

Apellis Pharmaceuticals Inc. shares APLS, +5.76% jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc. ALPMY, , o...

September 19, 2023, 8:38 am

Novartis' (nvs) sandoz gets rights for stelara biosimilar

Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America...

September 12, 2023, 1:35 pm

Promis neurosciences to present at the h.c. wainwright 25th annual global investment conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company foc...

September 6, 2023, 12:18 pm

Azure biotech announces educational initiative to create awareness of unmet women’s menopausal medical issue

Vulvovaginal atrophy (VVA), also known as the Genitourinary Syndrome of Menopause (GSM), affects over 3...

August 30, 2023, 4:55 pm

Scholar rock: the market isn't enthusiastic despite decent clinical data

Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular ...

August 27, 2023, 9:13 am

Biopharmaceutical stock soars on positive drug update

The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue w...

August 23, 2023, 11:22 am

Annexon highlights recent pipeline and business progress and reports second quarter 2023 financial results

ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic ...

August 7, 2023, 10:30 am

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)

SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safet...

July 30, 2023, 5:00 pm

Annexon presents archer trial results at asrs 2023 highlighting potential of anx007 as a differentiated treatment for geographic atrophy

Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for AN...

July 30, 2023, 4:00 pm

Apellis provides update on review of rare safety events with syfovre® (pegcetacoplan injection) for geographic atrophy

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive...

July 29, 2023, 6:52 pm

First-to-market edge for apellis’s syfovre in geographic atrophy diminished in the face of an unexpected safety signal

Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights Ex...

July 28, 2023, 4:26 pm

Belite bio doses first subject in pivotal phase 3 phoenix trial evaluating oral tinlarebant for ga

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD...

July 27, 2023, 9:00 pm

Annexon to report archer phase 2 trial results in geographic atrophy at asrs 2023

Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — ...

July 24, 2023, 10:30 am

Belite bio completes enrollment in pivotal global phase 3 dragon trial evaluating oral tinlarebant for stargardt disease

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD...

July 24, 2023, 10:04 am

Apellis: exercise caution in response to safety signal (rating downgrade)

Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic ...

July 18, 2023, 10:08 am

Immunic has a blockbuster clinical pipeline to treat multiple sclerosis and gastrointestinal diseases

New York-based biotechnology company Immunic Inc (NASDAQ:IMUX) has one or more potential blockbusters in its clinical pipeline. The firm's promising l...

June 16, 2023, 8:01 am

Annexon (annx) stock down more than 50% last week: here's why

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic ...

May 30, 2023, 11:55 am

Why shares of annexon are plummeting thursday

Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (...

May 25, 2023, 11:52 am


Search within

Pages Search Results: